Summit Therapeutics (SMMT) Non-Current Receivables (2021 - 2024)
Historic Non-Current Receivables for Summit Therapeutics (SMMT) over the last 4 years, with Q4 2024 value amounting to $698000.0.
- Summit Therapeutics' Non-Current Receivables fell 2721.58% to $698000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $698000.0, marking a year-over-year decrease of 2721.58%. This contributed to the annual value of $698000.0 for FY2024, which is 2721.58% down from last year.
- Latest data reveals that Summit Therapeutics reported Non-Current Receivables of $698000.0 as of Q4 2024, which was down 2721.58% from $467000.0 recorded in Q3 2024.
- Over the past 5 years, Summit Therapeutics' Non-Current Receivables peaked at $11.3 million during Q3 2021, and registered a low of $212000.0 during Q1 2024.
- In the last 4 years, Summit Therapeutics' Non-Current Receivables had a median value of $747000.0 in 2023 and averaged $2.4 million.
- Per our database at Business Quant, Summit Therapeutics' Non-Current Receivables plummeted by 7791.65% in 2023 and then plummeted by 2721.58% in 2024.
- Quarter analysis of 4 years shows Summit Therapeutics' Non-Current Receivables stood at $11.3 million in 2021, then crashed by 70.82% to $3.3 million in 2022, then plummeted by 70.95% to $959000.0 in 2023, then dropped by 27.22% to $698000.0 in 2024.
- Its Non-Current Receivables stands at $698000.0 for Q4 2024, versus $467000.0 for Q3 2024 and $364000.0 for Q2 2024.